468 related articles for article (PubMed ID: 1760899)
21. [Pharmacological approach to the platinum compounds].
Sasaki Y
Gan To Kagaku Ryoho; 1992 Apr; 19(4):456-62. PubMed ID: 1313667
[TBL] [Abstract][Full Text] [Related]
22. WR2721 as a modulator of cisplatin- and carboplatin-induced side effects in comparison with other chemoprotective agents: a molecular approach.
Treskes M; van der Vijgh WJ
Cancer Chemother Pharmacol; 1993; 33(2):93-106. PubMed ID: 8261581
[TBL] [Abstract][Full Text] [Related]
23. Platinum compounds in children with cancer: toxicity and clinical management.
Ruggiero A; Trombatore G; Triarico S; Arena R; Ferrara P; Scalzone M; Pierri F; Riccardi R
Anticancer Drugs; 2013 Nov; 24(10):1007-19. PubMed ID: 23962902
[TBL] [Abstract][Full Text] [Related]
24. Platinum-DNA adduct formation in leucocytes of children in relation to pharmacokinetics after cisplatin and carboplatin therapy.
Peng B; Tilby MJ; English MW; Price L; Pearson AD; Boddy AV; Newell DR
Br J Cancer; 1997; 76(11):1466-73. PubMed ID: 9400943
[TBL] [Abstract][Full Text] [Related]
25. Local distribution into brain tumor and pharmacokinetics of 4-pyridoxate diammine hydroxy platinum, a novel cisplatin derivative, after intracarotid administration in rats with 9L malignant glioma: simultaneous brain microdialysis study.
Tokunaga Y; Nakashima M; Sasaki H; Tomiyama N; Nakashima MN; Ichikawa M; Kaminogo M; Shibata S
Biol Pharm Bull; 2000 Dec; 23(12):1491-6. PubMed ID: 11145184
[TBL] [Abstract][Full Text] [Related]
26. Inductively coupled plasma mass spectroscopy quantitation of platinum-DNA adducts in peripheral blood leukocytes of patients receiving cisplatin- or carboplatin-based chemotherapy.
Bonetti A; Apostoli P; Zaninelli M; Pavanel F; Colombatti M; Cetto GL; Franceschi T; Sperotto L; Leone R
Clin Cancer Res; 1996 Nov; 2(11):1829-35. PubMed ID: 9816137
[TBL] [Abstract][Full Text] [Related]
27. The disposition of carboplatin in ovarian cancer patients.
Gaver RC; Colombo N; Green MD; George AM; Deeb G; Morris AD; Canetta RM; Speyer JL; Farmen RH; Muggia FM
Cancer Chemother Pharmacol; 1988; 22(3):263-70. PubMed ID: 3044634
[TBL] [Abstract][Full Text] [Related]
28. [Pharmacokinetic properties of platinium derivatives].
Boisdron-Celle M; Lebouil A; Allain P; Gamelin E
Bull Cancer; 2001 Aug; 88 Spec No():S14-9. PubMed ID: 11567909
[TBL] [Abstract][Full Text] [Related]
29. A rationale for carboplatin treatment and abdominal hyperthermia in cancers restricted to the peritoneal cavity.
Los G; Smals OA; van Vugt MJ; van der Vlist M; den Engelse L; McVie JG; Pinedo HM
Cancer Res; 1992 Mar; 52(5):1252-8. PubMed ID: 1737387
[TBL] [Abstract][Full Text] [Related]
30. Diethyldithiocarbamate inhibition of murine bone marrow toxicity caused by cis-diamminedichloroplatinum(II) or diammine-(1,1-cyclobutanedicarboxylato)platinum(II).
Gringeri A; Keng PC; Borch RF
Cancer Res; 1988 Oct; 48(20):5708-12. PubMed ID: 2844391
[TBL] [Abstract][Full Text] [Related]
31. Pharmacokinetics of platinum in cancer patients treated with carboplatin in combination with high-dose methotrexate.
el-Yazigi A; Amer M; Martin CR
Pharm Res; 1989 Jun; 6(6):492-6. PubMed ID: 2668915
[TBL] [Abstract][Full Text] [Related]
32. Intraperitoneal carboplatin infusion may be a pharmacologically more reasonable route than intravenous administration as a systemic chemotherapy. A comparative pharmacokinetic analysis of platinum using a new mathematical model after intraperitoneal vs. intravenous infusion of carboplatin--a Sankai Gynecology Study Group (SGSG) study.
Miyagi Y; Fujiwara K; Kigawa J; Itamochi H; Nagao S; Aotani E; Terakawa N; Kohno I;
Gynecol Oncol; 2005 Dec; 99(3):591-6. PubMed ID: 16095677
[TBL] [Abstract][Full Text] [Related]
33. Oxaliplatin: pharmacokinetics and chronopharmacological aspects.
Lévi F; Metzger G; Massari C; Milano G
Clin Pharmacokinet; 2000 Jan; 38(1):1-21. PubMed ID: 10668856
[TBL] [Abstract][Full Text] [Related]
34. Phase I study of intraperitoneal carboplatin as adjuvant therapy in early ovarian cancer.
Malmström H; Larsson D; Simonsen E
Gynecol Oncol; 1990 Dec; 39(3):289-94. PubMed ID: 2258073
[TBL] [Abstract][Full Text] [Related]
35. High accumulation of platinum-DNA adducts in strial marginal cells of the cochlea is an early event in cisplatin but not carboplatin ototoxicity.
Thomas JP; Lautermann J; Liedert B; Seiler F; Thomale J
Mol Pharmacol; 2006 Jul; 70(1):23-9. PubMed ID: 16569706
[TBL] [Abstract][Full Text] [Related]
36. Comparative distribution and excretion of carboplatin and cisplatin in mice.
Siddik ZH; Jones M; Boxall FE; Harrap KR
Cancer Chemother Pharmacol; 1988; 21(1):19-24. PubMed ID: 3277732
[TBL] [Abstract][Full Text] [Related]
37. Tissue platinum after clinical treatment with cisplatin or carboplatin in tumor-bearing patients.
Minami T; Tohno Y; Tohno S; Utsumi M; Yamada M; Hashii K; Tateyama I; Kadota E; Okazaki Y
Biol Trace Elem Res; 1997; 58(1-2):77-83. PubMed ID: 9363322
[TBL] [Abstract][Full Text] [Related]
38. Comparison of carboplatin pharmacokinetics between an anephric child and two children with normal renal function.
Koren G; Weitzman S; Klein J; Moselhy G
Med Pediatr Oncol; 1993; 21(5):368-72. PubMed ID: 8388075
[TBL] [Abstract][Full Text] [Related]
39. Pharmacokinetics of carboplatin administered with lobradimil to pediatric patients with brain tumors.
Warren K; Gervais A; Aikin A; Egorin M; Balis FM
Cancer Chemother Pharmacol; 2004 Sep; 54(3):206-12. PubMed ID: 15156345
[TBL] [Abstract][Full Text] [Related]
40. Pharmacokinetics of free and total platinum species after rapid and prolonged infusions of aqua (1,1-bis(aminomethyl)cyclohexane) sulfatoplatinum (II) (spiroplatin) during a phase I trial.
van der Vijgh WJ; Elferink F; Vermorken JB; ten Bokkel Huinink WW; Klein I; Gall HE; Simonetti G; McVie JG; Pinedo HM
Eur J Cancer Clin Oncol; 1988 Apr; 24(4):621-7. PubMed ID: 3383966
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
